In our recent study published in Scientific Reports, we sought to address these unmet needs by performing a comprehensive characterization of the tissue-level miRNA expression profiles of 2,606 miRNAs across a diverse cohort of TGCT subtypes, tissue sources (primary versus metastatic tissue), and treatment backgrounds.
Compared to existing studies in The Cancer Genome Atlas (TCGA), our research significantly expands the known miRNA repertoire in TGCT. By analyzing seminomas (SEM), non-seminomas (N-SEM), and teratomas, we discovered hundreds of miRNAs that are differentially enriched across these histological subtypes.
Importantly, we discovered specific miRNA signatures (including miR-143, miR-194, miR-199b, miR-200b, and miR-490) that are enriched in teratomas. Distinguishing teratoma from viable N-SEM or SEM is a frequent clinical dilemma, particularly in the post-chemotherapy setting, where surgical decisions for retroperitoneal lymph node dissection (RPLND) are made. We proposed several classifiers incorporating these markers that achieved high area under the receiver-operating curves (AUC), suggesting that these miRNAs could eventually serve as molecular markers to supplement traditional imaging and serum tests.
Beyond their potential as biomarkers, we performed a suite of computational analyses to dissect the molecular mechanisms underlying their clinical significance. We identified miRNA-mediated networks that appear to drive the epigenetic states of different subtypes. For example, we found that miR-200-3p is enriched in N-SEM and targets DNMT3B, a DNA methyltransferase known to be selectively high in N-SEM. This suggests that miRNAs can act as regulators of the epigenetic landscape that defines TGCT histological subtypes. Additionally, we mapped miRNA targets to a few well-known transcription factors, including FOXO and RUNX1, further implicating these transcription factor regulatory networks as driving tumorigenesis of TGCT subtypes, which are modulated by miRNAs.
Interestingly, we found an unexpected enrichment of somatotroph signaling pathways and anthropometric traits, such as height, in the genes targeted by our miRNA markers in TGCT. It has been reported that TGCT risk is associated with body height, and our analysis further supports the model where miRNAs may inform the mechanisms of genetic pleiotropy and improve the discovery of causal signals in complex traits.
Our work has several important clinical implications. By developing more accurate, non-invasive diagnostic assays to refine subtype classification and incorporating subtype-specific markers to predict treatment response, we hope to improve patient risk stratification and inform surgical planning for RPLND versus systemic therapies. Moreover, our findings provide a valuable resource to explore novel therapeutic strategies that modulate miRNA networks to sensitize resistant subtypes to conventional treatments. Ultimately, we envision that the incorporation of miRNA tests into the clinical workflow of TGCT will facilitate the transition toward a more personalized paradigm in TGCT management, with superior diagnostic accuracy and optimized survival outcomes for patients with TGCT.
Written by: Taibo Li,1 and Nirmish Singla,1-3
- James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Department of Urology, Medical University of Vienna, Vienna, Austria
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Read the Abstract